Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Alexion Pharmaceuticals, Inc. (ALXN)

NEW YORK, Nov. 18, 2016 -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Alexion Pharmaceuticals, Inc. (“Alexion” or the “Company”) (Nasdaq:ALXN) in the United States District Court for the Southern District of New York on behalf of purchasers of common stock of Alexion between February 10, 2014 through November 9, 2016 (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the Securities Exchange Act of 1934.

According to the Complaint, Defendants issued materially false and misleading statements to investors and/or failed to disclose that: (i) the Company employed improper sales practices with respect to Soliris; (2) consequently, the Company’s revenues from Soliris sales were unlikely to be sustainable; and (3) as a result, the Company’s public statements were materially false and misleading at all relevant times.  When the true details entered the market, the lawsuit claims that investors suffered damages.

If you wish to serve as lead plaintiff, you must move the Court no later than January 17, 2017.  A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.  If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].

Please visit our website at http://www.gme-law.com for more information about the firm.